Hollis-Eden updates on Neumune
San Diego, USA-based Hollis-Eden Pharmaceuticals says that it has been informed by the Department of Health and Human Services, in a letter dated June 23, that the firm "is within the competitive range for discussion and further evaluation" with respect to its response to the HHS' Request for Proposal No DHHS-ORDC-DDA-05-12 entitled Medical Countermeasures to Mitigate or Treat Neutropenia Alone or in Combination with Co-Morbidities Associated with Acute Radiation Syndrome (ARS).
This formally begins the negotiation process for a potential procurement of the company's Neumune, aimed at treating overexposure to radiation. The HHS indicated in its letter that the new estimated date of award is September 15.
The news sent Hollis-Eden's share price surging more than 7% to $5.08 on the day of the announcement, June 26.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze